Acute myelomonocytic leukemia (AMML) is a subtype of acute myeloid leukemia (AML) in which the leukemic blasts show both granulocytic (neutrophil-line) and monocytic differentiation. It corresponds to FAB M4. Clinically it matters because the monocytic component brings features such as gum and skin infiltration, hyperleukocytosis and central nervous system involvement. Its treatment follows modern AML practice, where genetics rather than morphology largely set prognosis and therapy.
This guide is written for clinicians and trainees who need a structured review of AMML diagnosis, risk assessment and management. It sits within the wider spectrum of hematologic disorders; for a patient-level overview, see our article on myelomonocytic leukemia.
Definition and Classification
In the French-American-British (FAB) system, M4 was defined by marrow blasts plus at least 20% granulocytic cells and at least 20% monocytic cells. A variant with abnormal marrow eosinophils, M4Eo, was recognized separately. The WHO classification lowered the blast threshold for AML from 30% to 20% and kept AMML as a morphologic category for cases without a defining genetic lesion.
The current WHO and International Consensus Classification systems first ask whether a defining genetic abnormality is present, such as CBFB::MYH11 or mutated NPM1. If one is, the case is classified by that lesion, and “myelomonocytic” becomes a descriptor of differentiation rather than the diagnosis itself. Morphologic AMML remains useful at the bedside, but genetics drive classification and treatment decisions.
Pathogenesis and Risk Factors
AMML arises from a myeloid progenitor that acquires mutations blocking maturation and driving proliferation. The resulting blasts accumulate in the bone marrow, causing bone marrow failure. Recurrent genetic findings include:
- inv(16)(p13.1q22) or t(16;16), creating CBFB::MYH11; this is the lesion classically seen in M4Eo and is a core-binding factor leukemia.
- NPM1 mutations, frequent in AML with monocytic features and often in a normal karyotype.
- FLT3 internal tandem duplication (ITD) or tyrosine kinase domain mutations, which raise leukocyte counts and relapse risk.
- KMT2A (MLL) rearrangements, more typical of monocytic and myelomonocytic leukemias and of therapy-related disease after topoisomerase II inhibitors.
Risk factors include prior chemotherapy or radiotherapy, benzene exposure, a preceding myelodysplastic or myeloproliferative neoplasm, and constitutional conditions such as Down syndrome. Most cases have no identifiable cause.
Clinical Presentation
Patients present with features of marrow failure: fatigue and pallor from anemia, bleeding and bruising from thrombocytopenia, and fever or infection from neutropenia. The monocytic component adds several distinctive findings:
- Gingival hypertrophy and leukemia cutis (skin infiltrates)
- Hepatosplenomegaly and lymphadenopathy
- Hyperleukocytosis, with a risk of leukostasis in the lungs and brain
- CNS involvement, more common than in other AML subtypes
- Coagulopathy, including disseminated intravascular coagulation, and tumor lysis syndrome
High serum and urine lysozyme levels, released by monocytic cells, can contribute to kidney injury. A white count above 100 x 10^9/L with breathlessness, hypoxia or neurological symptoms should be treated as an emergency.
Diagnostic Workup
The peripheral smear shows myeloblasts, monoblasts and promonocytes, often with circulating monocytes. Bone marrow aspiration and trephine biopsy establish the blast percentage (promonocytes count as blast equivalents) and the lineage mix, while providing samples for cytogenetics and molecular testing.
| Test | Granulocytic component | Monocytic component |
|---|---|---|
| Myeloperoxidase / Sudan black B | Positive | Weak or negative |
| Nonspecific esterase (alpha-naphthyl butyrate) | Negative | Positive, inhibited by sodium fluoride |
| Flow cytometry | CD13, CD33, CD117, CD34 (variable), MPO | CD14, CD64, CD11b, CD4, CD36 |
| Morphology | Myeloblasts, sometimes with Auer rods | Monoblasts and promonocytes with folded nuclei |
Double staining for chloroacetate esterase and nonspecific esterase can show both lineages on one slide. Baseline workup should also include a karyotype, FISH for CBFB::MYH11 where relevant, a molecular panel covering at least NPM1, FLT3, CEBPA, TP53 and KIT, coagulation studies, uric acid, lactate dehydrogenase and renal function. Consider a lumbar puncture if neurological symptoms are present, once coagulopathy and circulating blasts are controlled.
Risk Stratification and Treatment
Prognosis follows European LeukemiaNet (ELN) genetic risk rather than the M4 label. Core-binding factor AML with inv(16) and NPM1-mutated AML without adverse features sit in the favorable group, while TP53 mutations, complex karyotype and many KMT2A rearrangements are adverse.
Induction
Fit patients receive intensive induction, classically “7+3”: seven days of cytarabine and three days of an anthracycline such as daunorubicin or idarubicin. A FLT3 inhibitor such as midostaurin is added for FLT3-mutated disease, and gemtuzumab ozogamicin may be added for core-binding factor AML. Hyperleukocytosis is managed with hydration, hydroxyurea or prompt induction, and tumor lysis prophylaxis.
Supportive care
Supportive care carries particular weight in AMML. Monitor coagulation daily during induction and replace platelets, fibrinogen and plasma as needed. Give allopurinol or rasburicase, maintain urine output, and check potassium, phosphate, calcium and creatinine closely in the first days. Antimicrobial prophylaxis and rapid empirical treatment of neutropenic fever follow local AML protocols. Avoid red cell transfusion when the white count is very high unless it is clearly necessary, because it can worsen blood viscosity.
Consolidation and beyond
Favorable-risk patients usually receive high-dose or intermediate-dose cytarabine consolidation. Intermediate- and adverse-risk patients in first remission are generally referred for allogeneic stem cell transplantation. Older or unfit patients are commonly treated with a hypomethylating agent such as azacitidine combined with venetoclax. Measurable residual disease monitoring, for example by NPM1 or CBFB::MYH11 quantitative PCR, guides post-remission decisions. For a comparison with lymphoid disease management, see our review of Philadelphia chromosome-positive ALL, and for the broader AML context, our leukemia guide.
Key Takeaways
- AMML is AML with both granulocytic and monocytic differentiation, historically FAB M4.
- Gum and skin infiltration, hyperleukocytosis and CNS involvement reflect the monocytic component.
- Cytochemistry and flow cytometry confirm both lineages; cytogenetic and molecular testing define prognosis.
- inv(16) and NPM1 mutations are common and favorable; TP53 and complex karyotypes are adverse.
- Treatment is intensive induction with genotype-directed additions, then risk-adapted consolidation or transplant.
Frequently Asked Questions
How is AMML different from acute monocytic leukemia?
In AMML, both granulocytic and monocytic cells make up a substantial share of the leukemic population. In acute monoblastic or monocytic leukemia (FAB M5), the monocytic lineage dominates, with at least 80% of the non-erythroid cells being monocytic. The two share many clinical features, including gum and skin involvement.
Why does AMML cause gum swelling?
Leukemic monocytes readily migrate into tissues, including the gingiva and skin. Gum hypertrophy is therefore a classic clue to monocytic differentiation and should prompt a blood count in any patient who also has fatigue, fever or bruising.
Is AML with inv(16) the same as AMML with eosinophilia?
They overlap closely. Most M4Eo cases carry inv(16) or t(16;16), but current classifications define the entity by the CBFB::MYH11 fusion, regardless of morphology or blast count.
Does the M4 label change treatment?
Not directly. Treatment is chosen according to genetic risk, fitness and targetable mutations. The monocytic features mainly alert the clinician to watch for leukostasis, CNS disease, tissue infiltration and coagulopathy.
